CHARLESTOWN, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) — Strong Biosciences Inc. (Nasdaq: NASDAQ:) (the Firm or Strong), a life sciences firm growing precision genetic medicines for neuromuscular and cardiac ailments, at present introduced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will take part in a fireplace chat at Chardan’s 8th Annual Genetic Medicines Convention on Monday, September 30, 2024, at 11:00 am ET.
A dwell webcast of the hearth chat can be obtainable on the Occasions web page of the Buyers part of the Firm web site or by clicking right here. A webcast replay can be archived for 30 days on the Occasions web page.
Institutional buyers involved in assembly with administration through the conferences might attain out to their Chardan representatives.
About Strong Biosciences
Strong Biosciences is a precision genetic medication firm centered on advancing a portfolio of gene remedy candidates together with SGT-003 for the therapy of Duchenne muscular dystrophy (Duchenne), SGT-501 for the therapy of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the therapy of BAG3-mediated dilated cardiomyopathy, and extra property for the therapy of deadly cardiac ailments. Strong is advancing its numerous pipeline throughout uncommon neuromuscular and cardiac ailments, bringing collectively specialists in science, expertise, illness administration, and care. Affected person-focused and based by these immediately impacted, Strong’s mandate is to enhance the every day lives of sufferers residing with these devastating ailments. For extra info, please go to www.solidbio.com.
Strong Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Company Communications
Strong Biosciences Inc.
[email protected]
Media Contact:
Glenn Silver
FINN Companions
[email protected]